FreeTCCL Archive ASCO Releases Three Guidelines For Cancer Survivorship Care May 01, 2014Vol.37 No.04
FreeTCCL Archive LDK378 Demonstrates 58 Percent Overall Response Rate in Phase I May 01, 2014Vol.37 No.04
FreeTCCL Archive Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen May 01, 2014Vol.37 No.04
FreeTCCL Archive Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate May 01, 2014Vol.37 No.04
FreeTCCL Archive Oral Sorafenib Trial Published in The Lancet; Tablets Extend PFS in Metastatic Disease May 01, 2014Vol.37 No.04
FreeTCCL Archive Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival May 01, 2014Vol.37 No.04
Drugs & TargetsFreeTCCL Archive FDA Approves Cyramza for Stomach Cancer; Zykadia in NSCLC; Lipiodol for HCC Imaging; And Cobas HPV Test for Primary Screening May 01, 2014Vol.37 No.04
Drugs & TargetsFreeTCCL Archive European Commission Approves Subcutaneous Rituximab March 31, 2014Vol.37 No.03
